Ignyta, Inc. (Nasdaq: RXDX), a precision oncology
biotechnology company, today announced that the World Health
Organization (WHO) has approved the international nonproprietary name
(INN) “entrectinib” for the company’s lead product candidate, RXDX-101.
Sign-up for Ruthigen Announces First Patient Enrollment in the Phase 1/2 Human Clinical Trial of RUT58-60, a Broad-Spectrum Anti-Infective Drug Candidate Designed for Prophylactic Use During Invasive Surgery investment picks
Sign-up for Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration investment picks
In Voting Overwhelmingly on Broadfin's Gold Proxy Card Shareholders Followed the Recommendations of ISS and Glass Lewis Broadfin Looks Forward to a Refreshed Board with Five Recent Additions and the Opportunity to Create Immediate Positive Impact
NEW YORK , Dec.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.